On August 3, 2022, the Chinese website of the Fortune released the list of "Fortune Global 500" for 2022. In the list, China National Pharmaceutical Group Co., Ltd. (hereinafter referred to as Sinopharm) ranks 80th, the first place among global pharmaceutical enterprises.
It is 10th consecutive year for Sinopharm to be included in the list of "Fortune Global 500". Since it was included in the list in 2013 for the first time, Sinopharm has made its ranking rise for 9consecutive times. This year, its ranking has risen by 29 places compared with that of the previous year and has risen by 366 places in total.
Sinopharm is the only central enterprise directly under the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council with life and health as its main business. As an innovative enterprise of China, it is central pharmaceutical reserve and a leading integrated medical and healthcare industrial group with strong comprehensive strength and large scale. With over 1,600 subsidiaries and eight listed companies, it has an operating revenue of over RMB700 billion. Sinopharm gives top priority to the people and life. With the mission of "All for Health, Health for All", Sinopharm works tirelessly to meet the ever-growing expectation of the people for a healthy and better life.